@inbook{eecdc107ff3243569d0a9fe71b52f1c9,
title = "Mechanisms Driving Resistance to Proteasome Inhibitors Bortezomib, Carfilzomib, and Ixazomib in Multiple Myeloma",
abstract = "The first clinically available proteasome inhibitor (PI) bortezomib was trialed in multiple myeloma (MM) approximately two decades ago and has since become a mainstay of myeloma therapy, significantly enhancing the overall survival of patients. However, bortezomib resistance continues to be a significant hurdle in the treatment of MM, despite the introduction of next-generation PIs such as carfilzomib and ixazomib. Unlike resistance to some other targeted therapies such as tyrosine kinase inhibitors, bortezomib resistance is highly complex and is able to arise through multiple mechanisms. This chapter discusses the current known mechanisms underlying bortezomib resistance, as well as resistance to the next-generation proteasome inhibitors carfilzomib and ixazomib.",
keywords = "Multiple myeloma, Proteasome inhibitors, Bortezomib, Carfilzomib, Ixazomib, Proteasome inhibitor resistance, Autophagy, Unfolded protein response",
author = "Bennett, {Melissa K.} and Pitson, {Stuart M.} and Wallington-Beddoe, {Craig T.}",
year = "2021",
month = jul,
day = "24",
doi = "https://doi.org/10.1007/978-3-030-73440-4_4",
language = "English",
isbn = "9783030734398",
series = "Resistance of Targeted Anti-Cancer Therapeutics",
publisher = "Springer Nature",
pages = "39--59",
editor = "Silvia Ling and Trieu, {Steven }",
booktitle = "Resistance to Targeted Therapies in Multiple Myeloma",
}